HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New ...
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New Drug ...
Sun Pharmaceutical’s U.S.-based Taro Pharmaceutical Industries helped the Indian drugmaker boost its U.S. sales in its last fiscal year, but the skin care specialist has hit a small manufacturing ...
Desoximetasone 0.25%. Avoid use on eyes, face, axilla, or groin. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large ...
Perrigo Company plc PRGO recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals USA Inc.'s TARO Topicort spray, 0.25% (desoximetasone topical ...
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their ...
HAWTHORNE, N.Y. — Taro Pharmaceutical Industries reported last week that it has received approval from the Food and Drug Administration for its new drug application Topicort (desoximetasone) topical ...
Taro Receives FDA Approval For Topicort ® (desoximetasone) Topical Spray, 0.25% HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") reported today that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results